298P - Profile of male breast cancer: single institution study of 76 patients from Northern India

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Breast Cancer, Early Stage
Presenter Ajay Gogia
Authors A. Gogia1, V. Raina2, S.V.S. Deo3, B.K. Mohanti4, N.K. Shukla3
  • 1Medical Oncology, All India Institute of Medical Sciences (AIIMS) Institute Rotary Cancer Hospital, 110029 - New Delhi/IN
  • 2Dept. Of Medical Oncology & Haematology & Stem Cell Transplant, All India Institute of Medical Sciences (AIIMS) Institute Rotary Cancer Hospital, 110029 - New Delhi/IN
  • 3Surgical Oncology, AIIMS, 110029 - New Delhi/IN
  • 4Radiation Oncology, All India Institute of Medical Sciences (AIIMS) Institute Rotary Cancer Hospital, 110029 - New Delhi/IN

Abstract

Background

Male breast cancer (MBC) is a rare disease and accounts for 1 % of all breast cancer. The aim of our study was to assess clinical, pathological parameters and outcome in MBC.

Methods

This analysis was carried out in 76 male breast cancer patients with confirmed case of MBC who were registered in our breast cancer clinic between 1996-2011 at Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS). Analysis was performed with descriptive statistics, the log rank test was used to compare outcome.

Results

The median age was 56 years (range 28-80). The median duration of symptoms was 10 months (range 0.5-120). Breast lump was the commonest (93%) presenting symptom (right > left side). TNM Stage distribution was stage I -3 %, stage II- 20%, stage III- 55%, and stage IV- 22%. Positive family history was elicited in 8 (10.5%) patients. The median clinical tumour size was 3.9 cm. Modified Radical mastectomy was the commonest surgical procedure. IDC was the most common histology. Sixty percent of tumours were high grade and 55% had pathological node positive disease. ER/PR, her2neu status was available in 75% and 65% respectively. ER/PR and her2neu positivity was 90% and 30% respectively. Triple negative breast cancer (TNBC) constituted 20%. Median follow up was 36 months. Ten patients had relapsed of which 70% were distant, bone being the most common site followed by lung and liver. Five years disease free (DFS) and overall survival (OS) was 40% and 60%. Higher nodal stage, tumour size (>5 c.m.), negative ER/PR status, positive her2neu status, and visceral metastasis at baseline predicted poor outcome.

Conclusion

Our population had more advanced disease at presentation, higher her2neu positivity and higher triple negative status as compared to western population results in poorer outcome.

Disclosure

All authors have declared no conflicts of interest.